Primary Patency in Drug-Eluting Stenting Versus Bypass for Femoropopliteal Occlusive Disease
Journal of Surgical Research · 2025
DOI: 10.1016/j.jss.2025.09.075 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Surgical Research, 2025. Verfasst von Pooria Nakhaei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vascular & Endovascular Surgery, Department of Surgery, UC San Diego (UCSD), San Diego, California; Center for Learning and Excellence in…. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Popliteal Artery, Femoral Artery, Vascular Patency. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Numerous studies have compared the outcomes of bypass and bare-metal stent in the management of femoropopliteal occlusive disease. However, the available evidence has become scarce since the advent of paclitaxel drug-eluting stents (DESs). This study endeavors to assess and contrast the intermediate-termS real-world results of employing DES and bypass techniques in the treatment of individuals afflicted with femoropopliteal occlusive disease. MATERIALS AND METHODS: We identified all patients who underwent femoropopliteal revascularization at a single institution from January 2012 to December 2017. In this group, we selected all patients who received drug-eluting stents or underwent bypass using autogenous vein. We compared the primary patency, overall survival, and limb salvage at 2 y between the two groups. A comparison between the two groups within Trans-Atlantic Inter-Society Consensus (TASC) II subgroups was also performed. Multivariate Cox regression models were used to examine the treatment effect on the main outcomes. RESULTS: Of the study cohort, 129 patients (56.1%) received femoropopliteal bypass, while 101 patients (43.9%) underwent DES placement. Median follow-up time was 19 mo (interquartile range 11-29). Patients in the DES group were more likely to have TASC A and B lesions (77.2%), whereas 63% of patients in the bypass group had TASC C and D lesions. The overall 2-y primary patency estimates were 82.1% for the DES group compared to 59.2% for the bypass group (P 0.1). These findings persisted after stratification by TASC II subgroups. CONCLUSIONS: The use of DES in a real-practice setting was associated with a higher primary patency among patients with TASC A and B lesions, whereas bypass did not offer an advantage in terms of patency in longer lesions (TASC C and D). Further studies of larger populations are required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Vascular & Endovascular Surgery, Department of Surgery, UC San Diego (UCSD), San Diego, California; Center for Learning and Excellence in Vascular & Endovascular Research (CLEVER), UC San Diego, San Diego, C…
Zitieren
APA
Nakhaei, P., Mathlouthi, A., Khan, M. A., Zarrintan, S., & Malas, M. B. (2025). Primary Patency in Drug-Eluting Stenting Versus Bypass for Femoropopliteal Occlusive Disease. Journal of Surgical Research. https://doi.org/10.1016/j.jss.2025.09.075
Vancouver
Nakhaei P, Mathlouthi A, Khan MA, Zarrintan S, Malas MB. Primary Patency in Drug-Eluting Stenting Versus Bypass for Femoropopliteal Occlusive Disease. Journal of Surgical Research. 2025. doi:10.1016/j.jss.2025.09.075
BibTeX
@article{Nakhaei2025,
author = {Nakhaei, Pooria and Mathlouthi, Asma and Khan, Maryam Ali and Zarrintan, Sina and Malas, Mahmoud B},
title = {Primary Patency in Drug-Eluting Stenting Versus Bypass for Femoropopliteal Occlusive Disease},
journal = {Journal of Surgical Research},
year = {2025},
doi = {10.1016/j.jss.2025.09.075}
}
EUVIMED